Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinsonâ€™s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

11:36am	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
06-29	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI

Market Cap	18.62M 16.3M 15.02M 13.94M 26.47M 1.78B 26.83M 180M 69.96M 872M 69.91M 68.37M 3.02B	P/E 2024	-3.13x	P/E 2025	0.13x
Enterprise Value	32.44M 28.41M 26.17M 24.29M 46.12M 3.09B 46.75M 313M 122M 1.52B 122M 119M 5.27B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	55.3%	Yield 2024 *	-	Yield 2025	-

11:36am	Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites	CI
06-29	Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003	CI
06-22	Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc	CI
06-18	Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026	CI
06-17	Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services	CI
06-17	TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility	CI
06-08	Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development	CI
05-14	Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus	CI
04-30	Oncotelic Therapeutics Advances Toward Commercial Launch of Ai-Enabled Robotics Platform	CI
04-15	Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-06	Nightfood Holdings, Inc. and Oncotelic Therapeutics, Inc. Execute Joint Development, Manufacturing, and Licensing Agreement	CI

09:30am	Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway	AQ
06-29	Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003	AQ
06-18	Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026	AQ
06-17	Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services	AQ
06-08	Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote	AQ

Mateon Therapeutics, Inc. Stock OTC Markets

Stocks

MATN

US57667K1097

Biotechnology & Medical Research

Valuation: Mateon Therapeutics, Inc.

Latest news : Mateon Therapeutics, Inc.

Press Releases: Mateon Therapeutics, Inc.

Managers and Directors: Mateon Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Vuong Trieu CEO	Chief Executive Officer	61	2019-04-21
Amit Bhupendra Shah DFI	Director of Finance/CFO	59	2019-06-30
Seymour H. Fein CTO	Chief Tech/Sci/R&D Officer	77	2020-01-05

Director	Title	Age	Since
Vuong Trieu CHM	Chairman	61	2019-04-21
Steven King BRD	Director/Board Member	61	2020-05-10
Anthony Maida BRD	Director/Board Member	61	2020-05-10

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATEON THERAPEUTICS, INC.	-.--%	-.--%	-	-	18.62M
ARGENX SE	-0.10%	+0.10%	+74.33%	+133.26%	57.73B
WUXI APPTEC CO., LTD.	-3.80%	-6.24%	+67.04%	+86.36%	54.69B
BIONTECH SE	+0.12%	+0.67%	-14.88%	-12.34%	23.75B
INSMED INCORPORATED	+1.46%	+5.92%	+16.48%	+468.63%	24.18B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	+4.25%	+40.38%	-3.72%	19.82B
GENMAB A/S	+3.78%	+5.65%	+44.99%	-26.23%	17.14B
PHARMAESSENTIA CORPORATION	+3.46%	+17.72%	+206.66%	+364.07%	16.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.81%	+18.00%	+41.99%	-	15.57B
EXELIXIS, INC.	+3.06%	+5.17%	+29.59%	+196.35%	13.96B
Average	+0.34%	+5.56%	+56.29%	+150.80%	27.06B
Weighted average by Cap.	-0.38%	+3.34%	+57.90%	+139.33%

	2024	2025
Net sales	-	-
Net income	-4.52M -3.96M -3.65M -3.39M -6.43M -432M -6.52M -43.68M -17M -212M -16.99M -16.62M -734M	249M 218M 201M 187M 354M 23.78B 359M 2.41B 937M 11.67B 936M 916M 40.47B
Net Debt	13M 11.39M 10.49M 9.74M 18.49M 1.24B 18.74M 126M 48.86M 609M 48.83M 47.76M 2.11B	13.82M 12.11M 11.15M 10.35M 19.66M 1.32B 19.92M 133M 51.95M 647M 51.91M 50.77M 2.24B